Alginate Oral and Nasal Composition for Stable Nicotine Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compositions for delivering biologically active agents to the oral or nasal cavity face challenges in maintaining stability and controlled release of agents like nicotine, especially under high water content conditions, while ensuring compliance and avoiding degradation during manufacturing and storage.
Innovation Solution
Compositions comprising alginate as a matrix forming agent, ammonium citrate as an antioxidant, and a filling agent, which stabilize the active agent and control its release rate, using a pH-adjusted formulation to enhance stability and user compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If alginate matrix is used as matrix forming agent, then release characteristics and stabilization of active agents are improved, but additional antioxidant protection is still needed for very liable active agents during long term storage
Solution Approach 1:
The patent combines alginate matrix with antioxidants (such as ascorbic acid, tocopherols, or citric acid) to create a composite formulation. The alginate provides the primary stabilization mechanism through its gel structure and ion exchange properties, while the antioxidants provide additional protection against oxidative degradation during long term storage, creating a multi-layered stabilization system that addresses the limitations of alginate alone.
2Ease of operation
If high water content is used in compositions, then compliance and user comfort are improved, but degradation of liable active agents increases during storage
Solution Approach 1:
The patent optimizes the water content parameter within a specific range (typically 20-60% w/w) to balance user comfort and storage stability. Additionally, the patent adjusts pH parameters and incorporates antioxidants that are effective at the optimized water content levels, creating a formulation where the active agent remains stable despite the presence of water, while still providing adequate compliance and user comfort.
3Speed
If nicotine is delivered through oral or nasal cavity, then fast therapeutic onset is achieved, but degradation under heat, oxygen and light influence occurs
Solution Approach 1:
The patent incorporates antioxidants and stabilizers into the formulation before the active agent is exposed to degrading conditions during storage or manufacturing. This preliminary protection allows the nicotine to maintain its stability throughout manufacturing and storage processes, while still enabling fast therapeutic onset when delivered to the oral or nasal cavity, as the protective agents are already in place to prevent degradation.
4Ease of operation
If conventional tobacco products are mimicked, then user compliance is improved, but degradation and local irritation issues persist
Solution Approach 1:
The patent extracts and removes the harmful components from conventional tobacco products, retaining only the desirable delivery mechanism and sensory characteristics. By formulating nicotine-free or with reduced nicotine content alongside stabilizing agents and antioxidants, the product mimics the user experience of conventional tobacco products while eliminating or reducing the harmful degradation products and local irritation associated with traditional combustion-based delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide stable, controlled release of active agents with enhanced storage stability and user compliance, maintaining a suitable pH and minimizing degradation, particularly effective for nicotine delivery.
Implementation Method 1
WO 2010/0104464 indicates that the alginate matrix may form an oxygen barrier
Implementation Method 2
a complex binding antioxidant... comprising at least one ammonium citrate or a salt thereof
Data Source
AI summary
The specification discloses compositions for use in the oral or nasal cavity comprising a biologically active agent, a matrix forming agent comprising alginate and suitable salts thereof, a filling agent and at least one antioxidant that is an effective complex binder. The compositions can further comprise additional excipients such as preservatives, taste or flavour enhancers, pH adjusters, plasticizers and sweeteners. The specification also discloses methods of producing the compositions.